Onconova Therapeutics, Inc. Announces Results of Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split

NEWTOWN, Pa., May 20, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual meeting of stockholders.  At the annual meeting, Onconova stockholders voted to approve a reverse stock split of the company’s common stock by a ratio of not less than one-for-eight and not more than one-for-twelve.  The company’s board of directors subsequently fixed the reverse stock split ratio at one-for-ten and fixed the record date for the reverse stock split.

The one-for-ten reverse stock split of Onconova’s common stock will take effect at 5:00 PM EDT on Tuesday, May 31, 2016.  Onconova’s common stock will begin trading on a post-split basis on Wednesday, June1, 2016.  Stockholders at the effective time will receive one new share of common stock for every ten shares that they hold.  Onconova will not issue any fractional shares as a result of the reverse split.  Instead, Onconova’s stockholders who otherwise would have been entitled to a fraction of a share will receive a full share of common stock.

The reverse stock split is intended primarily to increase the per share bid price of Onconova’s common stock and satisfy the NASDAQ Capital Market continued listing requirement.

At the annual meeting, Onconova’s stockholders also approved a reduction of the number of authorized shares of common stock from 75,000,000 to 25,000,000, elected each of the board’s eight director nominees to the board of directors, and ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the 2016 fiscal year.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.  For more information, please visit  http://www.onconova.com .

About Rigosertib

Rigosertib is a small molecule inhibitor of cellular signaling and acts as a RAS mimetic. These effects of rigosertib appear to be mediated by direct binding of the compound to the RAS-binding domain (RBD) found in many RAS effector proteins, including the Raf kinases and PI3K. The therapeutic focus for rigosertib is myelodysplastic syndromes (MDS), a group of bone marrow disorders characterized by ineffective formation of blood cells that often converts into acute myeloid leukemia (AML). Clinical trials for rigosertib are being conducted at leading institutions in the United States, Europe, and the Asia-Pacific region. Rigosertib is protected by issued patents (earliest expiry in 2026) and has been awarded Orphan Designation for MDS in the United States, Europe and Japan.

About INSPIRE

The IN ternational S tudy of P hase III I V R igos E rtib, or INSPIRE, is based on guidance received from the  U.S. Food and Drug Administration and European Medicines Agency and derives from the findings of the ONTIME Phase 3 trial.  INSPIRE is a multi-center, randomized controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within the first nine months of initiation of HMA treatment.  This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines.  The trial will enroll approximately 225 patients randomized at a 2:1 ratio into two treatment arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.  The primary endpoint of INSPIRE is overall survival and an interim analysis is anticipated. Full details of the INSPIRE trial, such as inclusion and exclusion criteria, as well as secondary endpoints, can be found on clinicaltrials.gov (NCT02562443). 

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or Onconova Therapeutics, Inc.'s future operations, clinical development of Onconova's product candidates and presentation of data with respect thereto, regulatory approvals, expectations regarding the sufficiency of Onconova's cash and other resources to fund operating expenses and capital expenditures, Onconova's anticipated milestones and future expectations and plans and prospects. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including Onconova’s need for additional financing and current plans and future needs to scale back operations if adequate financing is not obtained, the success and timing of Onconova’s clinical trials and regulatory approval of protocols, and those discussed under the heading “Risk Factors” in Onconova’s most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT: CONTACT: Onconova Therapeutics Benjamin Hoffman, 267-759-3036 bhoffman@onconova.us

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

XPLR Infrastructure Faces Class Action Lawsuit Outcry

Updated Category News Views 170

Class Action Lawsuit Filed Against XPLR Infrastructure Levi & Korsinsky, LLP has announced a class action lawsuit concerning XPLR Infrastructure, LP, previously known as Nextera Energy Partners, LP. This lawsuit addresses significant concerns regarding securities fraud that impacted numerous investors, particularly those who held shares during the specified time frame....

Continue Reading
PharmAla Reports Impressive Growth and Key Milestones Achieved

Updated Category News Views 291

PharmAla Biotech Holdings Shareholder Update PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has recently shared their financial and operational performance metrics providing insight into their notable achievements up to the end of May 2025. Focusing on the development and distribution of LaNeo™ MDMA, along with other novel...

Continue Reading
Discover the Bold New Batch of Sagamore Spirit Rye Whiskey

Updated Category News Views 387

Discover the Bold New Batch of Sagamore Spirit Rye Whiskey The 100% Maryland-made whiskey is 7-Years-Old and 123 Proof Sagamore Spirit, the celebrated Maryland rye distillery, is introducing a new batch of their award-winning Cask Strength Rye Whiskey. This exceptional spirit boasts a seven-year age profile and carries a robust ABV of 61.5%. The whiskey delights the...

Continue Reading
Stocks to Eye: Ciena, Oracle, and Other Market Movers Ahead

Updated Category News Views 166

Market Trends to Watch This Thursday As U.S. stock futures experience a downward shift, investors are keenly eyeing some significant stocks that could impact market movements today. Among them, several prominent companies are set to announce their earnings, potentially affecting their stock performance and overall market sentiment. Ciena Corp. on Investor's Radar Wall...

Continue Reading
The Perfect Franchise Conference Boosts Industry Engagement

Updated Category News Views 144

The Perfect Franchise Annual Conference: A Catalyst for Growth The Perfect Franchise (TPF), a leader in the realm of franchise consulting and coaching, has seen notable advancements, particularly in the wake of their annual conference. As the franchise industry blooms, this gathering serves not just as an event but as a beacon of growth for both franchise brands and...

Continue Reading